ARTICLE | Clinical News
Dacetuzumab: Phase Ib data
December 14, 2009 8:00 AM UTC
Data from a dose-escalation Phase Ib trial in 36 patients with relapsed or refractory MM showed that 4-12 mg/kg dacetuzumab in combination with Revlimid lenalidomide and dexamethasone produced 2 comp...